SAN DIEGO--(BUSINESS WIRE)--Biocom, the association representing the life science industry of California, issued the following statement regarding passage of H.R.2430, the FDA Reauthorization Act (FDARA) of 2017 in the U.S. Senate. The House approved the bill on July 12.
“Today, the Senate passed important legislation that will ensure that the Food and Drug Administration (FDA) continues to have the resources to review and approve new products and technologies,” said Joe Panetta, president and CEO of Biocom. “It also takes significant steps to incorporate patient perspectives into the drug development process, facilitate the use of innovative clinical trial designs and real-world evidence, and improve communication, accountability and predictability.”
“The bill is essential to the success of California’s more than 12,000 life science establishments, which are at the cutting edge of science and biomedical innovation. Biocom applauds the work of the House and Senate in passing landmark legislation in an exemplary show of bipartisanship that will help advance 21st century medicine and give hope to patients globally,” added Panetta.
Biocom is the largest, most experienced leader and advocate for California’s life science sector. We work on behalf of more than 950 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs.
Founded in 1995 in San Diego, Biocom provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to its San Diego headquarters, Biocom operates a core office serving the Los Angeles market, satellite offices in Washington, D.C. and Tokyo, and has a continuous staff presence in the San Francisco Bay area and Sacramento. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers.